GSK signs sport anti-doping deal

GlaxoSmithKline has signed a deal with the World Anti-Doping Agency (Wada) to help scientists develop early detection methods for drugs that have performance-enhancing potential in sport.

GSK will supply Wada with confidential information about drugs it has in early stage development that could potentially be abused by athletes once they are on the market, under a deal announced yesterday which covers all drugs being developed.

Sports including cycling and athletics have been plagued in recent years by top-level athletes abusing banned substances – including the blood booster EPO, human growth hormone and testosterone.